Novartis, Monte Rosa strike $5.7 billion drug development deal

Reuters
Sep 15
Novartis, Monte Rosa strike $5.7 billion drug development deal

Sept 15 (Reuters) - Swiss drugmaker Novartis NOVN.S and drug developer Monte Rosa Therapeutics GLUE.O signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases.

(Reporting by Kamal Choudhury in Bengaluru; Editing by Tasim Zahid)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10